Hyperviscosity syndrome happens when blood becomes too “thick” to flow easily through small vessels. That thickness can rise quickly—often because of very high blood proteins from a blood cancer—or build more gradually when the body makes too many blood cells. Either way, sluggish flow can reduce oxygen delivery and strain the heart, brain, and eyes. People may notice blurry vision, headaches, nosebleeds, or unusual sleepiness, sometimes after a short period of feeling “off” without a clear reason.
This condition matters because it can turn into an emergency. The most effective treatments work best when started early, sometimes before every lab result is back. The goal of this guide is to help you recognize typical patterns, understand what causes them, and know what modern care looks like—from the first evaluation to long-term prevention.
Table of Contents
- What hyperviscosity syndrome is and why it can be urgent
- What causes hyperviscosity and who is at risk
- Symptoms and complications to watch for
- How hyperviscosity syndrome is diagnosed
- Treatment options and what to expect in hospital
- Aftercare, prevention, and when to seek help
What hyperviscosity syndrome is and why it can be urgent
Blood is meant to be fluid enough to slip through tiny vessels in the eyes, brain, kidneys, and fingertips. Hyperviscosity syndrome (HVS) describes the point where blood becomes thick enough to slow that flow and cause symptoms. It is less a single disease and more a final pathway—many different problems can lead to the same “traffic jam” in the circulation.
Two broad mechanisms explain most cases:
- Protein-driven hyperviscosity (serum hyperviscosity): Blood contains an unusually high amount of proteins, usually immunoglobulins made by abnormal plasma cells or lymphoplasmacytic cells. These proteins increase friction in the liquid part of blood and can also make red cells clump together.
- Cell-driven hyperviscosity (whole-blood hyperviscosity): The body produces too many cells (red cells, white cells, or platelets), or the cells behave in a way that makes flow less smooth. In these cases, the “crowding” rather than the protein is the dominant issue.
Why it can be urgent comes down to where the slow flow shows up first. The smallest vessels are often affected early, which is why symptoms commonly involve:
- Eyes: blurred vision, “smudged” vision, or visual field changes.
- Brain: headache, dizziness, confusion, imbalance, drowsiness, or—rarely—seizures.
- Mucosal surfaces: nosebleeds, gum bleeding, or easy bruising.
Clinicians sometimes describe a classic triad—neurologic symptoms, visual changes, and mucosal bleeding. Not everyone has all three, but the pattern is common enough that it shapes emergency decision-making.
A practical insight that helps patients understand their care: doctors may treat suspected HVS based on symptoms and exam findings even before viscosity results return. That is because early treatment can quickly restore flow and prevent irreversible injury, especially to the retina and central nervous system.
Finally, “thick blood” is not always the same as “high clot risk.” Hyperviscosity can increase clotting risk in some settings, but it can also cause bleeding, especially when abnormal proteins interfere with platelets and clotting factors. That mix—bleeding and clotting risk in the same patient—is one reason HVS requires careful, expert management rather than generic advice.
What causes hyperviscosity and who is at risk
Hyperviscosity syndrome is most often linked to conditions that dramatically increase blood proteins or blood cells. Knowing the common causes helps you understand why the workup may include blood cancer testing even if you came in for “just” nosebleeds or blurry vision.
Common protein-driven causes include:
- Waldenström macroglobulinemia: A frequent cause of symptomatic serum hyperviscosity because IgM proteins are large and mostly stay within the bloodstream. Symptoms often appear when IgM levels are very high, but there is no single “safe” number—people vary.
- Multiple myeloma: More commonly linked to IgA or IgG proteins. Hyperviscosity can occur, but it may require higher protein levels than in IgM-related disease.
- Cryoglobulinemia (especially type I): Abnormal proteins can precipitate or aggregate and contribute to thickening and small-vessel symptoms, sometimes with cold sensitivity.
Common cell-driven causes include:
- Polycythemia vera or other erythrocytosis: Too many red blood cells increase whole-blood viscosity and can reduce flow in the brain and extremities.
- Leukemia with very high white cell counts (leukostasis overlap): Very high leukocyte levels can impair microcirculation and mimic or coexist with hyperviscosity physiology.
- Extreme thrombocytosis: Very high platelet counts can contribute to abnormal flow and bleeding/clotting complications.
Risk factors are often about the underlying disorder and the pace of change:
- Known plasma cell or lymphoplasmacytic disorders: People with established diagnoses may be monitored for rising immunoglobulin levels and symptoms.
- Delayed diagnosis of a blood cancer: Hyperviscosity can be the first dramatic clue, especially if earlier symptoms (fatigue, weight loss, neuropathy, recurrent infections) were subtle.
- Dehydration or diuretic use: Not a primary cause, but dehydration can concentrate proteins and cells and worsen symptoms.
- Recent rituximab exposure in IgM disease: Some patients experience a temporary IgM rise (“IgM flare”) that can precipitate symptoms unless preventive steps are taken.
- Cold exposure in cryoprotein states: Cold can promote protein precipitation, worsening circulation in fingers, toes, and ears.
A useful “risk lens” is to ask: is the viscosity problem driven by proteins, cells, or both? That distinction affects urgent treatment. For example, removing proteins quickly requires therapeutic plasma exchange, while removing excess red cells often requires phlebotomy. In some patients—such as those with both high proteins and anemia—clinicians must sequence treatments carefully to avoid worsening oxygen delivery while lowering viscosity.
If you have a known blood disorder, don’t rely on numbers alone. A rising lab value may be concerning, but symptoms and exam findings are what define the syndrome. Conversely, new neurologic or visual symptoms deserve evaluation even if your last labs looked “acceptable.”
Symptoms and complications to watch for
Hyperviscosity syndrome can look different from person to person, but it often follows recognizable patterns. Symptoms tend to reflect impaired microcirculation—small vessels are the first to struggle when blood becomes too thick.
Typical symptoms include:
- Visual changes
- Blurred or “hazy” vision
- Double vision or transient visual loss
- Difficulty reading fine print that is new for you
- Eye discomfort or a sense that vision “dims” with exertion
- Neurologic symptoms
- Headache that is new, persistent, or unusually intense
- Dizziness, vertigo, imbalance, or slowed thinking
- Confusion, unusual sleepiness, or personality change noticed by family
- Tingling or numbness that is new or rapidly worsening
- Bleeding and bruising
- Nosebleeds or gum bleeding
- Easy bruising or prolonged bleeding from minor cuts
- Heavy menstrual bleeding beyond your usual pattern
- Circulatory and general symptoms
- Shortness of breath with minimal exertion
- Chest pressure or a sense of racing heart
- Fatigue that feels “heavy,” not just tired
- Cold, painful fingers or toes in cryoprotein states
Clinicians often look for eye findings because the retina provides a direct window into microvascular strain. Retinal hemorrhages, dilated “sausage-like” veins, and other changes can support the diagnosis and help gauge urgency.
Complications depend on the cause and severity:
- Stroke-like events: Reduced flow and abnormal clotting can contribute to transient ischemic attacks or strokes. This risk is one reason sudden neurologic symptoms are treated as emergencies.
- Heart strain and fluid overload: Thick blood increases resistance. People with pre-existing heart disease may develop worsening shortness of breath or signs of heart failure.
- Kidney injury: Poor perfusion and the underlying disorder (such as myeloma) can both threaten kidney function.
- Severe vision loss: Rare, but delayed treatment can allow retinal injury that does not fully reverse.
A practical “red flag” list is helpful for non-clinicians. Seek urgent evaluation for any of the following:
- Sudden or rapidly worsening vision changes
- New confusion, severe headache, fainting, or seizure
- Persistent nosebleeds or bleeding that does not stop with pressure
- New weakness on one side, facial droop, or trouble speaking
- Shortness of breath at rest or chest pain that is new or severe
One more nuance: symptoms can worsen after dehydration, infection, or certain therapies. If you have a known plasma cell disorder and you become acutely ill, it is reasonable to be more vigilant. A “small” change—like a new headache with blurry vision—can be the first clue that viscosity has crossed a threshold where urgent treatment helps.
How hyperviscosity syndrome is diagnosed
Diagnosis starts with clinical suspicion. Because hyperviscosity syndrome can progress quickly, clinicians prioritize the question, “Does this patient have signs of impaired microcirculation right now?” while also working to identify the underlying cause.
A typical evaluation includes:
History and bedside assessment
Clinicians ask about the timeline and pattern of symptoms—especially vision changes, headaches, dizziness, bleeding, and shortness of breath. They also review known blood disorders, recent treatments, and factors that concentrate blood (vomiting, diarrhea, poor intake, diuretics).
The physical exam may focus on:
- Neurologic status (alertness, coordination, strength)
- Signs of bleeding (nose, gums, skin)
- Hydration status and blood pressure
- Heart and lung findings that suggest strain or fluid overload
Eye examination
An urgent eye evaluation (often with fundoscopy) can be highly informative. Retinal vein engorgement, hemorrhages, or other classic changes can support a decision to treat promptly, even before viscosity results return.
Laboratory testing to confirm viscosity and find the cause
Key tests often include:
- Serum viscosity (when serum hyperviscosity is suspected)
- Complete blood count to assess red cells, white cells, and platelets
- Comprehensive metabolic panel with kidney function
- Immunoglobulin quantification and tests that detect abnormal proteins (for example, serum protein electrophoresis and related studies)
- Coagulation tests when bleeding is present or procedures are planned
- Additional targeted testing based on context, such as cryoprotein evaluation or infectious workup
A crucial clinical point: viscosity numbers and protein levels do not perfectly predict symptoms. Two people with similar lab values can feel very different. That’s why clinicians treat the syndrome—symptoms plus supportive findings—rather than treating a number in isolation.
Imaging and specialized testing
Imaging is not always required to diagnose HVS, but it may be used to evaluate complications or the underlying disease:
- Brain imaging for focal neurologic symptoms or severe headache
- Chest imaging if severe shortness of breath or suspected heart failure is present
- Bone marrow evaluation when a plasma cell or lymphoplasmacytic disorder is suspected
Because hyperviscosity can involve both bleeding and clotting risks, teams also plan procedures carefully. For example, if plasma exchange is likely, they may coordinate vascular access, bleeding evaluation, and calcium monitoring (because citrate anticoagulation can lower calcium during procedures).
In practice, diagnosis and initial treatment often proceed together: stabilize the patient, reduce viscosity promptly if symptoms are significant, and then confirm the cause and build a definitive long-term plan.
Treatment options and what to expect in hospital
Treatment has two goals: rapid symptom relief by improving blood flow and durable prevention by treating the underlying disease. Many patients feel better quickly once viscosity drops, but the episode can recur if the cause is not controlled.
Immediate stabilization
Common early steps include:
- Careful hydration if appropriate (often intravenous fluids), balanced against the risk of fluid overload
- Oxygen and cardiorespiratory monitoring when symptoms are severe
- Avoiding medications that could worsen bleeding or drop blood pressure without a clear need
Clinicians may treat based on high suspicion—especially when visual or neurologic symptoms are prominent—because waiting can increase the chance of lasting harm.
Therapeutic plasma exchange for protein-driven hyperviscosity
Therapeutic plasma exchange (also called plasmapheresis) removes the patient’s plasma—which contains the excess proteins—and replaces it with a substitute fluid such as albumin, sometimes with additional products depending on the situation. Practical expectations:
- Symptom improvement can be rapid, sometimes within hours.
- One session may be enough for meaningful relief in some patients, while others need repeated sessions based on symptoms and lab trends.
- Monitoring is important for blood pressure changes, electrolyte shifts (especially calcium), and bleeding risk.
Plasma exchange is a “bridge,” not the finish line. It reduces viscosity quickly, but it does not stop abnormal cells from producing more protein.
Phlebotomy and other apheresis approaches for cell-driven hyperviscosity
When excess cells drive viscosity:
- Phlebotomy lowers red cell concentration and can reduce symptoms in erythrocytosis.
- Leukapheresis may be used in select cases with extreme leukocytosis and microcirculatory compromise, often alongside urgent disease-directed therapy.
- Management of extreme thrombocytosis may involve cytoreductive treatment and careful bleeding/clotting assessment.
The correct approach depends on which component—protein, red cells, white cells, platelets—is creating the flow problem.
Definitive therapy for the underlying cause
After urgent viscosity control, clinicians move quickly to disease-directed treatment. Examples include:
- Targeted therapy, immunotherapy, or chemotherapy for Waldenström macroglobulinemia or myeloma
- Cytoreductive therapy for myeloproliferative disorders
- Treatment of contributing conditions such as cryoprotein-associated disease
A practical safety detail: in IgM-related disease, some therapies can temporarily raise IgM levels. Teams may plan preventive steps—sometimes including pre-treatment plasma exchange—when the risk of an acute viscosity spike is significant.
What recovery often looks like
Patients commonly notice that headaches and visual symptoms improve first. Fatigue can linger longer, especially if anemia, infection, or the underlying cancer is still active. Before discharge, teams often clarify:
- What symptoms require immediate return
- Which labs will be rechecked and when
- When definitive therapy starts or continues
- Whether you need outpatient apheresis or close follow-up
The best outcomes come from treating the emergency and the engine behind it, with a plan that prevents “rebound” hyperviscosity.
Aftercare, prevention, and when to seek help
After an HVS episode, prevention focuses on two layers: controlling the underlying condition and reducing day-to-day factors that can amplify symptoms. Many patients find that once they understand their personal triggers and monitoring plan, anxiety drops and confidence returns.
Follow-up monitoring that matters
Your team may recommend scheduled checks of:
- Abnormal protein levels or immunoglobulins (for plasma cell or lymphoplasmacytic disorders)
- Blood counts (for cell-driven causes)
- Kidney function and electrolytes
- Symptoms that correlate strongly with viscosity changes, especially vision and neurologic signs
Ask your clinician which marker is most useful for you. For some, it’s an immunoglobulin level trend; for others, it’s the hematocrit or a specific protein measurement pattern.
Practical steps that can reduce symptom swings
These steps do not replace medical treatment, but they can reduce vulnerability:
- Hydration consistency: Avoid large swings in fluid intake. If you have heart or kidney disease, follow your clinician’s specific fluid guidance rather than general advice.
- Illness planning: Fever, vomiting, or diarrhea can concentrate blood and worsen symptoms. Know when to call early rather than waiting.
- Medication review: Confirm whether you should avoid certain drugs that raise bleeding risk, and ask about over-the-counter products that contain stimulants.
- Cold precautions when cryoproteins are involved: Protect hands and feet in cold environments and avoid prolonged exposure that can worsen circulation.
Preventing recurrence through definitive therapy
If your HVS was caused by a blood cancer, preventing recurrence usually depends on controlling the abnormal cell population. Plasma exchange can provide rapid relief, but long-term stability comes from effective disease-directed treatment. If your condition is chronic, the plan may include:
- A clear threshold for when you should report symptoms
- A protocol for urgent evaluation if vision or neurologic symptoms appear
- A coordinated approach if a therapy is known to cause transient protein rises
When to seek care immediately
Return urgently—or call emergency services—if you develop:
- Sudden visual loss or rapidly worsening blurred vision
- New confusion, severe headache, fainting, or seizure
- Weakness on one side, facial droop, or difficulty speaking
- Uncontrolled bleeding (nose, gums, gastrointestinal bleeding signs)
- Shortness of breath at rest or chest pain that is new or severe
If symptoms are mild but new—such as a persistent headache with subtle vision changes—contact your care team the same day. Hyperviscosity is one of the few situations where “early and cautious” is usually the right instinct.
Living after hyperviscosity syndrome often means living with a plan: you know the warning signs, you know which labs matter, and you have a clear pathway for rapid treatment if symptoms return.
References
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue 2023 (Guideline)
- The role of therapeutic plasma exchange in plasma cell disorders – PMC 2024 (Review)
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management – PMC 2023 (Review)
- Cryoglobulinemia – PubMed 2022 (Review)
- Acute hyperviscosity: syndromes and management – PMC 2018 (Seminal Review)
Disclaimer
This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Hyperviscosity syndrome can be a medical emergency and requires prompt evaluation by qualified clinicians. If you have new vision changes, neurologic symptoms, severe headache, fainting, uncontrolled bleeding, chest pain, or shortness of breath, seek urgent medical care. For ongoing care, follow a personalized plan from your healthcare team, since the safest treatment depends on the underlying cause and your overall health.
If you found this guide helpful, please share it on Facebook, X (formerly Twitter), or any platform you prefer, and follow us on social media. Your support helps our team continue producing clear, trustworthy health content.
